HomeFLNA • NASDAQ
add
Filana Therapeutics, Inc
Previous close
$2.00
Day range
$1.91 - $2.00
Year range
$1.91 - $2.27
Market cap
92.25M USD
Avg Volume
95.47K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.70M | -36.37% |
Net income | -12.54M | 54.56% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -9.18M | 68.57% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 95.50M | -25.72% |
Total assets | 118.36M | -24.87% |
Total liabilities | 43.95M | 271.56% |
Total equity | 74.40M | — |
Shares outstanding | 48.31M | — |
Price to book | 1.30 | — |
Return on assets | -19.25% | — |
Return on capital | -30.62% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -12.54M | 54.56% |
Cash from operations | -9.75M | 84.09% |
Cash from investing | -501.00K | -778.95% |
Cash from financing | -329.00K | -135.84% |
Net change in cash | -10.58M | 82.49% |
Free cash flow | -4.32M | 64.46% |
About
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
Founded
1998
Headquarters
Employees
17
